Lung Cancer

A number of influential clinical trials were presented during the 2020 ASCO Virtual Scientific Program, 8 of which Stephen Liu, MD, discusses in depth in a virtual presentation during the 2020 ASCO Direct Highlights webcast.

The combination of nivolumab and ipilimumab provided similar clinical benefit to that of chemotherapy when given as a frontline treatment for patients with advanced non–small cell lung cancer who had stable and treated brain metastases at baseline.

Tiragolumab in combination with atezolizumab (Tecentriq) demonstrated early clinical activity and was found to be well tolerated in patients with advanced solid tumors, including those with metastatic non–small cell lung cancer who were PD-L1 positive and had not received prior checkpoint inhibition.

Leora Horn, MD, MSc, discusses data from an updated analysis of the phase 3 IMpower133 trial, which examined the first-line combination of atezolizumab (Tecentriq), carboplatin, and etoposide in small cell lung cancer.

Plasma-based next-generation sequencing continues to offer a minimally invasive, highly specific modality to identify patients with actionable alterations in non–small cell lung cancer.

Circulating tumor DNA clearance of EGFR mutation may be predictive of prolonged progression-free survival for patients with EGFR-mutant, MET-amplified non–small cell lung cancer with detectable ctDNA at baseline.

Balazs Halmos, MD, MS, discusses recent advancements made in non–small cell lung cancer.

The China National Medical Products Administration has accepted a supplemental new drug application for tislelizumab in combination with chemotherapy for the frontline treatment of patients with advanced nonsquamous non–small cell lung cancer.

The combination of atezolizumab plus carboplatin/etoposide continued to demonstrate an improvement in overall survival versus chemotherapy alone as a frontline treatment for patients with extensive-stage small cell lung cancer.

Robert Rintoul, BSc, MB ChB, PhD, FRCP, discusses the importance of minimal residual disease assessment in patients with non–small cell lung cancer.

In our exclusive interview, Everett Vokes, MD, discusses the path that led him to specialize in head and neck cancer and lung cancer, personal and professional challenges he encountered along the way, and the ultimate importance of bringing multimodality therapy to the forefront of treatment.

Roy S. Herbst MD, PhD, discusses the ADAURA trial and the impressive data seen with adjuvant osimertinib and highlights ongoing research efforts being made with the agent in lung cancer.

The United Kingdom’s National Institute for Health and Care Excellence has recommended entrectinib (Rozlytrek) as a treatment option for ROS1-positive advanced non–small cell lung cancer in adults who have not received prior treatment with ROS1 inhibitors.

The FDA has approved lurbinectedin (Zepzelca) for the treatment of adult patients with metastatic small cell lung cancer with disease progression, following platinum-based chemotherapy.

The 4-drug ABCP regimen improved survival while maintaining good health-related quality of life in patients with nonsquamous non–small cell lung cancer, according to patient-reported outcomes from the phase 3 IMpower150 trial.

Jean Lopategui, MD, discusses the evolution of targeted therapies in non–small cell lung cancer.

Hatim Husain, MD, discusses common misconceptions that still exist with regard to lung cancer.

Delvys Rodriguez-Abreu, MD, discusses findings from the final analysis of the phase 3 KEYNOTE-189 study in metastatic nonsquamous non–small cell lung cancer.

David R. Gandara, MD, an esteemed lung cancer specialist and 2017 Giants of Cancer Care® award winner, views himself not only as a physician-scientist, but also as an educator and communicator.

The Data and Safety Monitoring Board has advised that the phase 3 DUBLIN-3 trial of the antineoplastic agent plinabulin in patients with advanced or metastatic non–small cell lung cancer who have progressed on standard-of-care therapy can continue without any modifications.

Julia K. Rotow, MD, discusses the results of an ongoing phase 1/2 trial evaluating the safety and efficacy of osimertinib in combination with gefitinib as a first-line treatment for patients with stage IV EGFR-mutant non–small cell lung cancer.

Delvys Rodriguez-Abreu, MD, discusses the final analysis of the phase 3 KEYNOTE-189 study in metastatic nonsquamous non–small cell lung cancer.